Will requires a stem cell transplant to give him the best possible chance of recovery. Anyone aged 16-30 can register to become a stem cell donor via @AnthonyNolan
@SearsonEmma@Chris621121 Thank you for considering running for a charity with your ballot place! We'd love to have you as part of Team AN 💚
(We also have incredible cheer squads around the whole course to give you all the motivation and good vibes needed to complete the marathon too!)
A great morning with @AnthonyNolan, meeting stem cell donation recipients and talking about their experiences.
Get yourself on the blood stem cell donation register!!
🔬 A CAR‑T therapy used for blood cancer could also help ‘reset’ the immune system in severe lupus.
In the CARLYSLE trial, obe‑cel put 5/6 patients with severe lupus into remission - an early but promising sign for autoimmune treatment.
🔗https://t.co/OzpX2gQmxQ
We welcome this decision by NICE and will continue to advocate for access to this treatment on behalf of patients and families.💚
Find out more: https://t.co/A26YsjZMSx
In December, NICE published final guidance recommending the removal of Tecartus for patients with relapsed or refractory mantle cell lymphoma from the NHS.
We submitted a joint appeal with @bloodcancer_uk and @LymphomaAction and today NICE announced they will reconsider.
Applications to the stem cell register from Black people rose by more than 1,600% after Nidahl Hamdan, 24, began sharing her mother’s battle with blood cancer on social media.
@anthonynolan called the response ‘amazing’.
https://t.co/50DdFMyfF8
We welcome this positive news for our community and will continue advocating for more innovative treatments that improve the lives of patients to be made available.
For more information or support, we're here on 0303 303 0303 or [email protected] 💚
Today we're pleased to share that an additional CAR-T treatment, Breyanzi (liso-cel) has been approved by @NICEComms.
This will be available in England and Wales for patients with large B-cell lymphoma, if they have relapsed or stopped responding after 2 or more prior treatments